Bimagrumab

Drug Profile

Bimagrumab

Alternative Names: BYM-338

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator MorphoSys; Novartis
  • Developer Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action Type II-B activin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inclusion body myositis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Inclusion body myositis
  • Phase II Cachexia; Muscular atrophy

Most Recent Events

  • 28 Dec 2016 Novartis plans a phase II trial for Type-2 diabetes mellitus in USA (NCT03005288)
  • 11 Nov 2016 Efficacy and adverse events data from the phase II/III RESILIENT trial in Inclusion body myositis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals
  • 01 Aug 2016 Novartis Pharmaceuticals completes a phase II/III trial in Inclusion body myositis in USA (NCT02250443)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top